ProsTIC key research

Latest Published Research

• The UpFrontPSMA Trial: Lu-PSMA in men with newly diagnosed prostate cancer
• The ENZA-p Phase 2 Trial: Lu-PSMA with Enzalutemide in patients with metastatic castration-resistant prostate cancer. 
• The Lancet Comission On Prostate Cancer: Planning for the surge in cases. 
• The LuTectomy Trial: Lu-PSMA prior to radical prostatectomy.  
• The TheraP Phase 2 Trial: Lu-PSMA vs Cabazitaxel in metastatic castration-resistant prostate cancer.
• [68Ga]Ga-DPI-4452: First-in-human safety, imaging, and dosimetry of the peptide in patients with clear cell renal cell carcinoma.

Selected Top 10 Research papers with Impact

1. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021 February 11.
   Practice changing first RCT of 177Lu-PSMA-617, a novel treatment for men with metastatic prostate cancer. First author and study chair. Oral presentations at ASCO Annual and ASCO GU: 2020, 2021, 2022 
2. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet Oncol. 2020 
   Landmark 10-site RCT establishing PSMA PET/CT as a new standard-of-care in comparison to CT/bone scanning. Presented as EAU20 plenary. FDA approval of 68Ga-PSMA-11 2020. Cited in 2021 NCCN guidelines 
3. 18F-fluciclovine PET-CT vs 68Ga-PSMA-11 PET-CT: a prospective, single-centre, single-arm, comparative imaging trial. Lancet oncol. 2019 
   Practice changing study, contributed to FDA approval 2020 
4. Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. Am Soc Clin Oncol Educ Book. 2022
5. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet oncol. 2018 June 1.
   First-in-field publication. Led to Endocyte/AAA / Novartis $2b acquisition, multiple ph2/3 studies. 
6. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiograph. 2018
   Highly cited Radiographics manuscript based on award winning RSNA presentation 
7.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. European Urol. 2016
   Widely cited meta-analysis. 2020 update also published with >350 citations 
8. The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. J Nucl Med. 2022 
9. The Additive Diagnostic Value of Prostate- specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021
   Awarded EAU Scientific Manuscript of the Year 2021 
10. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022 

Other Original Research 

1. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. Eur Urol Oncol. 2023
2. TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2023 
3. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2023
4. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer—a systematic review and meta-analysis. Prostate Cancer Prostatic Dis, 2023 
5. Dose-Response Relationship Between Radiation Therapy and Loss of Lung Perfusion Comparing Positron Emission Tomography and Dual-Energy Computed Tomography in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023
6. Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nat Commun. 2023 
7. A VISION Substudy of Reader Agreement on 68GaPSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2023
8. Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy. BJU Int. 2023 
9. Novel radionuclide therapy combinations in prostate cancer. Therapeutic Advances in Medical Oncology, 2023
10. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2023 
11. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023
12.  A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy. Eur Urol Open Sci. 2023 
13. A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. Radiology. 2023 
14. Treatment de- intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky? BJU Int. 2023
15. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer. BJU Int. 2023
16. Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy. EJNMMI Res. 2023
17. Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer. Front Oncol. 2023 
18. Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clin Transl Radiat Oncol. 2023 
19. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023 
20. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023 
21. Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: A nested, qualitative longitudinal study. PLoS One. 2022 
22. A 2022 International Survey on the Status of Prostate Cancer Theranostics. J Nucl Med. 2023
23. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up. Cancer Imaging. 2022
24. PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up. Cancers (Basel). 2022 
25. Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. Front Oncol. 2022. 
26. Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clin Transl Radiat Oncol. 2022
27. 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. J Nucl Med. 2022
28. High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. BJU Int. 2022
29. Radiation Dosimetry in 177Lu-PSMA-617 Therapy. Semin Nucl Med. 2022 
30. The Additive Diagnostic Value of Prostate- specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021 
31. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021 
32. Advanced prostate cancer experimental radioactive treatment-clinical trial decision making: patient experiences. BMJ Support Palliat Care. 2021 
33. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021 
34. ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int. 2021
35. Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality? J Nucl Med. 2021 
36. UpFrontPSMA: A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naïve Prostate Cancer. BJU Int. 2021
37. Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study. Front Med 2021 
38. Automated assessment of functional lung imaging with 68Ga-ventilation/perfusion PET/CT using iterative histogram analysis. EJNMMI Phys. 2021
39. The role of 18F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective study. J Surg Oncol. 2021 
40. Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay. Cancer Imaging. 2021
41. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. Eur Urol. 2021
42. Utility of 68Ga-DOTA-Exendin-4 PET/CT imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. Intern Med J. 2021
43. Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. Eur Urol Focus. 2020
44. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. J Clin Oncol. 2020  
45. Efficacy and Safety of 177Lu-labeled Prostate- specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. Eur Urol. 2020  
46. Use of PSMA PET/CT in Response Assessment Following Upfront Chemohormonal Therapy in Metastatic Prostate Cancer. BJU Int. 2020  
47. Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer. Eur Urol 2020
48. 68Ga-PSMA PET in advanced prostate cancer - updated diagnostic utility, sensitivity and specificity and distribution of PSMA-avid lesions: A systematic review and meta-analysis. Eur Urol 2020
49. Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial. Eur Urol (in press). 
50. Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. Eur Urol Focus. 2021 
51. UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU Int. 2021
52. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int. 2020 

Review Articles and Clinical Guidelines 

1. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024
2. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer. Nat Rev Urol. 2024
3. May the Nuclear Medicine be with you! Neuroendocrine tumours and the return of nuclear medicine. Eur J Nucl Med Mol Imaging. 2024
4. Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy. Radiology. 2024
5. Role of FDG PET/CT in Management of Patients with Prostate Cancer. Semin Nucl Med. 2023.
6. Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2023 
7. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023
8. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol. 2023 
9. The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. J Nucl Med. 2022 
10. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023
11. Next Generation Radiotheranostics Promoting Precision Medicine. Ann Oncol. 2023 
12. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023
13. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2023.
14. [68 Ga]Ga-PSMA Versus [18 F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. Eur Urol Oncol. 2022
    Winner European Urology Oncology #SoMe award (most influential article according to PlumX Metrics)  
15. 177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer. Radiology. 2023
16. Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. Am Soc Clin Oncol Educ Book. 2022 
    ASCO 2022 Educational Feature Presentation
17. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022
18. Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics. J Nucl Med. 2021 
19. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. Eur Urol Oncol. 2021
20. Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. Eur Urol Oncol. 2021 
21. Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021 
22. The role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncol. 2021  
23. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA- PET. Eur J Nucl Med Mol Imaging. 2021
24. Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. Eur Urol Oncol. 2021
25. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. Eur Urol Oncol. 2021  
26. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate. 2020 .  
27. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer. Curr Opin Urol. 2020  
28. PSMA Theranostics in advanced prostate cancer: an evolving option. BJU Int. 2020
29. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 
30. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. Nat Rev Urol. 2020 .  
31. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis. 2019 
32. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. Curr Opin Urol. 2019
33. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019 

Editorials and Commentaries

1. Navigating the Future of Prostate Cancer Care: AI-Driven Imaging and Theranostics Through the Lens of RELAINCE. J Nucl Med. 2024
2. Radioactive Iodine: A Living History. J Nucl Med. 2024
3. Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy. J Nucl Med. 2024
4. Is 161Tb Really Happening? J Nucl Med. 2024
5. The Accomplishments and Legacy of Saul Hertz, MD. J Nucl Med. 2024
6. The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics. J Nucl Med. 2023 
7. FAPI PET/CT: a new kid on the block for RCC. Eur J Nucl Med Mol Imaging. 2023 
8. Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation. J Nucl Med. 2023 
9. Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging? J Nucl Med. 2023 
10. Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky? BJU Int. 2023 
11. Editorial Comment on Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). J Urol. 2023 
12. More Accurate Imaging Is Not Stage Migration: Time To Move from "Hubble" to "Webb" in Hormone-sensitive Prostate Cancer. Eur Urol. 2023 
13. Role of Prostate-Specific Membrane Antigen PET in Metastatic Prostate Cancer: We Have the Answers. J Nucl Med. 2022 
14. Leading in Urology and Pioneering in Social Media Outreach: A Conversation J Nuc Med, 2022 
15. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022 
16. Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. BJU Int. 2022
17. Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics. J Nucl Med. 2021
18. Targeted radioactive therapy for prostate cancer - Authors' reply. Lancet. 2021
19. Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jérémie Calais. J Nucl Med. 2021 
20. PSMA PET/CT for staging and treatment of prostate cancer. Clin Adv Hematol Oncol. 2019 
21. Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength? Eur Urol. 2019   
22. Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. BJU Int. 2019 
23. A Self-Fulfilling Prophecy: Comparing (177)Lu-PSMA Radioligand therapy in Taxane Naïve vs Post-Taxane metastasized Prostate Cancer Patients? J Nucl Med. 2019
24. Where to Next for Theranostics in Prostate Cancer? Eur Urol Oncol. 2019 
25. Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. J Clin Oncol. 2019
26. Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. Eur Urol. 2019